Id est avocats advised aMoon Fund and Swisscom Ventures in Sophia Genetics’ CHF 110 million Series F financing round
Sophia Genetics’, operating in Data-Driven Medicine, announced the closing of a $110 million financing round to enter into the next stage of its expansion, with a focus on supporting the growing clinical and biopharma demand for Data-Driven Medicine worldwide.
This Series F round was led by aMoon, a leading health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group. The company also received the trust of prime financial institutions Credit Suisse and the Pictet group. Existing investors Swisscom Ventures, Endeavour Vision, Generation Investment Management, Alychlo, and Eurazeo Growth participated in the round, as well as newcomers ACE & Company and Famille C Invest.
Id est avocats advised aMoon Fund and Swisscom Ventures in Sophia Genetics’ CHF 110 million Series F financing round. The team was led by Mehmet Toral (pictured) and included Marina Castelli, Basile Walder, Stéphanie Junod and Leo Schonenberger.